Cargando…

The intraocular pressure-lowering properties of intravenous paracetamol

AIM: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical timolol, oral acetazolamide, and no treatment. METHODS: A prospective, randomized, investigator-blind, parallel...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Heever, Henning, Meyer, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948718/
https://www.ncbi.nlm.nih.gov/pubmed/27471373
http://dx.doi.org/10.2147/OPTH.S87988
_version_ 1782443319646748672
author van den Heever, Henning
Meyer, David
author_facet van den Heever, Henning
Meyer, David
author_sort van den Heever, Henning
collection PubMed
description AIM: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical timolol, oral acetazolamide, and no treatment. METHODS: A prospective, randomized, investigator-blind, parallel-group study was conducted in 73 eyes of 52 subjects. Subjects received a single dose of IV paracetamol (1 g), oral acetazolamide (250 mg), topical timolol (0.5%, one drop), or no treatment. Baseline IOP was measured, and the measurement was repeated at 1, 2, 4, and 6 hours after treatment. RESULTS: Paracetamol reduced IOP from baseline by −10.8% (95% confidence interval [CI]: −4.9% to −16.8%, P=0.146) at 1 hour, −13.3% (95% CI: −8.3% to −18.4%, P=0.045) at 2 hours, −11.8% (95% CI: −5.5% to −18.4%, P=1.000) at 4 hours, and −23.9% (95% CI: −17.8% to −30.1%, P=0.006) at 6 hours after treatment. In the no-treatment group, the change was −2.9% (95% CI: +1.0% to −6.7%, P= referent) at 1 hour, −2.1% (95% CI: +2.9% to −7.2%, P= referent) at 2 hours, −7.6% (95% CI: −3.9% to −11.2%, P= referent) at 4 hours, and −6.9% (95% CI: −3.6% to −10.2%, P= referent) at 6 hours. Acetazolamide reduced IOP by −18.8% (95% CI: −12.7% to −24.8%, P=0.000) at 1 hour, −26.2% (95% CI: −18.2% to −34.2%, P=0.001) at 2 hours, −24.6% (95% CI: −16.9% to −32.3%, P=0.000) after 4 hours, and −26.9% (95% CI: −19.6% to −34.3%, P=0.000) 6 hours after treatment. Timolol reduced IOP by −31.2% (95% CI: −26.7% to −35.7%, P=0.000) at 1 hour, −27.7% (95% CI: −20.7% to −34.8%, P=0.000) at 2 hours, −28.7% (95% CI: −21.1% to −36.2%, P=0.000) at 4 hours, and −21.3% (95% CI: −13.4% to −30.0%, P=0.030) at 6 hours after treatment. The average change in IOP for the no-treatment group was −4.8% (95% CI: −2.6% to −6.9%, P= referent). It was −15.7% (95% CI: −9.3% to −22.1%, P=0.021) for paracetamol, −23.1% (95% CI: −16.4% to −29.8%, P=0.000) for acetazolamide, and −25.3% for the timolol group (95% CI: −19.4% to −31.2%, P=0.000). The maximal change in IOP for the no-treatment group was −9.2% (95% CI: −3.2% to −15.3%, P= referent). It was −25.9% (95% CI: −16.6% to −35.2%, P=0.009) for paracetamol, −33.8% (95% CI: −25.5% to −42.1%, P=0.000) for acetazolamide, and −36.8% (95% CI: −31.0% to −42.5%, P=0.000) for the timolol group. CONCLUSION: Intravenously administered paracetamol shows IOP-lowering properties over the first 6 hours after administration. Clinicians performing IOP measurements in patients who have received IV paracetamol in the preceding 6 hours should interpret these measurements with caution. Further studies are needed to investigate the IOP-changing properties of paracetamol.
format Online
Article
Text
id pubmed-4948718
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49487182016-07-28 The intraocular pressure-lowering properties of intravenous paracetamol van den Heever, Henning Meyer, David Clin Ophthalmol Original Research AIM: The aim of this paper was to investigate the intraocular pressure (IOP)-changing properties of a single standard dose of intravenous (IV) paracetamol and compare it to that of topical timolol, oral acetazolamide, and no treatment. METHODS: A prospective, randomized, investigator-blind, parallel-group study was conducted in 73 eyes of 52 subjects. Subjects received a single dose of IV paracetamol (1 g), oral acetazolamide (250 mg), topical timolol (0.5%, one drop), or no treatment. Baseline IOP was measured, and the measurement was repeated at 1, 2, 4, and 6 hours after treatment. RESULTS: Paracetamol reduced IOP from baseline by −10.8% (95% confidence interval [CI]: −4.9% to −16.8%, P=0.146) at 1 hour, −13.3% (95% CI: −8.3% to −18.4%, P=0.045) at 2 hours, −11.8% (95% CI: −5.5% to −18.4%, P=1.000) at 4 hours, and −23.9% (95% CI: −17.8% to −30.1%, P=0.006) at 6 hours after treatment. In the no-treatment group, the change was −2.9% (95% CI: +1.0% to −6.7%, P= referent) at 1 hour, −2.1% (95% CI: +2.9% to −7.2%, P= referent) at 2 hours, −7.6% (95% CI: −3.9% to −11.2%, P= referent) at 4 hours, and −6.9% (95% CI: −3.6% to −10.2%, P= referent) at 6 hours. Acetazolamide reduced IOP by −18.8% (95% CI: −12.7% to −24.8%, P=0.000) at 1 hour, −26.2% (95% CI: −18.2% to −34.2%, P=0.001) at 2 hours, −24.6% (95% CI: −16.9% to −32.3%, P=0.000) after 4 hours, and −26.9% (95% CI: −19.6% to −34.3%, P=0.000) 6 hours after treatment. Timolol reduced IOP by −31.2% (95% CI: −26.7% to −35.7%, P=0.000) at 1 hour, −27.7% (95% CI: −20.7% to −34.8%, P=0.000) at 2 hours, −28.7% (95% CI: −21.1% to −36.2%, P=0.000) at 4 hours, and −21.3% (95% CI: −13.4% to −30.0%, P=0.030) at 6 hours after treatment. The average change in IOP for the no-treatment group was −4.8% (95% CI: −2.6% to −6.9%, P= referent). It was −15.7% (95% CI: −9.3% to −22.1%, P=0.021) for paracetamol, −23.1% (95% CI: −16.4% to −29.8%, P=0.000) for acetazolamide, and −25.3% for the timolol group (95% CI: −19.4% to −31.2%, P=0.000). The maximal change in IOP for the no-treatment group was −9.2% (95% CI: −3.2% to −15.3%, P= referent). It was −25.9% (95% CI: −16.6% to −35.2%, P=0.009) for paracetamol, −33.8% (95% CI: −25.5% to −42.1%, P=0.000) for acetazolamide, and −36.8% (95% CI: −31.0% to −42.5%, P=0.000) for the timolol group. CONCLUSION: Intravenously administered paracetamol shows IOP-lowering properties over the first 6 hours after administration. Clinicians performing IOP measurements in patients who have received IV paracetamol in the preceding 6 hours should interpret these measurements with caution. Further studies are needed to investigate the IOP-changing properties of paracetamol. Dove Medical Press 2016-07-13 /pmc/articles/PMC4948718/ /pubmed/27471373 http://dx.doi.org/10.2147/OPTH.S87988 Text en © 2016 van den Heever and Meyer. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
van den Heever, Henning
Meyer, David
The intraocular pressure-lowering properties of intravenous paracetamol
title The intraocular pressure-lowering properties of intravenous paracetamol
title_full The intraocular pressure-lowering properties of intravenous paracetamol
title_fullStr The intraocular pressure-lowering properties of intravenous paracetamol
title_full_unstemmed The intraocular pressure-lowering properties of intravenous paracetamol
title_short The intraocular pressure-lowering properties of intravenous paracetamol
title_sort intraocular pressure-lowering properties of intravenous paracetamol
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948718/
https://www.ncbi.nlm.nih.gov/pubmed/27471373
http://dx.doi.org/10.2147/OPTH.S87988
work_keys_str_mv AT vandenheeverhenning theintraocularpressureloweringpropertiesofintravenousparacetamol
AT meyerdavid theintraocularpressureloweringpropertiesofintravenousparacetamol
AT vandenheeverhenning intraocularpressureloweringpropertiesofintravenousparacetamol
AT meyerdavid intraocularpressureloweringpropertiesofintravenousparacetamol